trending Market Intelligence /marketintelligence/en/news-insights/trending/gxeqaZu7SidoyVQ6c85_1g2 content esgSubNav
In This List

Adaptive Biotechnologies, Illumina team up to develop cancer diagnostic tests

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Adaptive Biotechnologies, Illumina team up to develop cancer diagnostic tests

Adaptive Biotechnologies Corp. signed a nonexclusive agreement with Illumina Inc. to develop in-vitro diagnostic test kits for cancer detection.

Under the agreement, the test kits will expand the availability of Seattle-based Adaptive's clonoSEQ system — used for assessing the level of cancer cells remaining in patients who are being treated for or have been treated for certain blood cancers — and immunoSEQ Dx IVD test kits for immunodiagnostics applications that are under development.

Adaptive said in a Sept. 24 press release that the test kits will make it possible for U.S. hospitals and health systems to run the company's tests in their local laboratories.

San Diego-based Illumina will create software for Adaptive to support the use of the new kits with its diagnostic sequencing instrument, called NextSeqDx. Illumina will provide regulatory and related support for the parts of the kits it provides while Adaptive will be responsible for obtaining necessary regulatory approvals and for the commercialization of the devices.

Illumina will retain ownership of the new software, subject to an exclusive license to Adaptive, which will retain ownership of the kits. Each company will distribute and otherwise commercialize its respective products.

Adaptive will pay to Illumina two milestone payments related to software development, subject to conditions. The companies will also share revenue on net sales of the products.

The agreement will expire Sept. 24, 2025, and either party could terminate the deal, subject to conditions.